Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04049799 · ClinicalTrials.gov registry record
Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions
A clinical trial, sponsored by University of Vermont.
- Completed
- Registry status
- 88
- Enrollment target
NCT04049799: Completed study, sponsored by University of Vermont.
NCT04049799 is a clinical trial that has completed, run by University of Vermont. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04049799 has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
Study Summary
This study will compare medically-supervised withdrawal (MSW, 'detoxification') to opioid agonist treatment (OAT, 'maintenance') with buprenorphine for pregnant women with opioid use disorder in terms of maternal, fetal, and neonatal outcomes. Outcomes will be assessed during pregnancy, at birth and for 12 months postpartum. This study has the potential to impact health service policy and practices in terms of the treatment options of pregnant women with opioid use disorder.
Interventions
- OTHER Medically-supervised withdrawal
- OTHER Opioid agonist treatment
- BEHAVIORAL Comprehensive clinical care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2019-08-08 |
| Est. Completion | 2024-02-01 |
What the finished NCT04049799 record still lists
NCT04049799 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 88 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Medically-supervised withdrawal is the first listed.
NCT04049799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04049799 about?
NCT04049799 is a clinical study titled "Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions". This study will compare medically-supervised withdrawal (MSW, 'detoxification') to opioid agonist treatment (OAT, 'maintenance') with buprenorphine for pregnant women with opioid use disorder in terms of maternal, fetal, and neonatal outcomes. Outcomes will be assessed during pregnancy, at birth and...
What is the current status of trial NCT04049799?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2019-08-08. Estimated completion is 2024-02-01.
What interventions are being tested in trial NCT04049799?
The interventions under investigation include: Medically-supervised withdrawal (OTHER), Opioid agonist treatment (OTHER), Comprehensive clinical care (BEHAVIORAL).
Who is sponsoring clinical trial NCT04049799?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI